Cargando…
Anlotinib Suppressed Ovarian Cancer Progression via Inducing G2/M Phase Arrest and Apoptosis
Ovarian cancer remains the most common gynecologic malignancy, because of its chemotherapy resistance and relapse. Anlotinib, a new oral multi-targeted tyrosine kinase inhibitor, has shown encouraging antitumor activity in several preclinical and clinical trials, while its effect on ovarian cancer h...
Autores principales: | Zhu, Yanghui, Wang, Xiaoyu, Chen, Zhaoyang, Zhou, Lingyan, Di, Xiangjie, Fan, Ping, He, Zhiyao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821756/ https://www.ncbi.nlm.nih.gov/pubmed/36614964 http://dx.doi.org/10.3390/jcm12010162 |
Ejemplares similares
-
Knockdown of DLGAP5 suppresses cell proliferation, induces G(2)/M phase arrest and apoptosis in ovarian cancer
por: Zhang, Huijun, et al.
Publicado: (2021) -
Combination of anlotinib and gemcitabine promotes the G0/G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma in vitro
por: Fan, Shanshan, et al.
Publicado: (2021) -
Romidepsin Induces G2/M Phase Arrest and Apoptosis in Cholangiocarcinoma Cells
por: Li, Pihong, et al.
Publicado: (2020) -
ZGDHu-1 induces G(2)/M phase arrest and apoptosis in Kasumi-1 cells
por: XIA, JUN, et al.
Publicado: (2015) -
Cardamonin induces G2/M phase arrest and apoptosis through inhibition of NF-κB and mTOR pathways in ovarian cancer
por: Ruibin, Jiang, et al.
Publicado: (2020)